Arcutis (ARQT) insider sale: 20,739 shares planned ($415,574)

Arcutis Biotherapeutics (ARQT) filed a Form 144 reporting a proposed sale of 20,739 common shares through Merrill Lynch with an aggregate market value of $415,574, planned for 10/02/2025.

Rhea-AI Filing Summary

Arcutis Biotherapeutics (ARQT) filed a Form 144 reporting a proposed sale of 20,739 common shares through Merrill Lynch with an aggregate market value of $415,574, planned for 10/02/2025. The shares were acquired on 03/01/2025 via restricted stock vesting. The filing lists 119,905,078 shares outstanding for the company, which provides context for the relative size of the sale. The filer, identified in past-sales records as Todd Franklin Watanabe, sold a total of 45,937 shares in the prior three months for gross proceeds of $812,132 across four transactions dated 08/04/2025, 09/08/2025, 09/09/2025, and 10/01/2025. The filer certifies they are not aware of undisclosed material adverse information.

Positive

• 20,739 shares to be sold were acquired via restricted stock vesting (03/01/2025)
• Filer made the required disclosure and attests to no undisclosed material adverse information

Negative

• Insider sold 45,937 shares in the past three months for gross proceeds of $812,132
• Planned sale equals ~0.0173% of reported 119,905,078 shares outstanding (based on filing figures)

Insights

Insider Transactions Analyst

TL;DR: Insider is selling restricted shares totaling 20,739 planned and 45,937 sold in last 3 months.

The Form 144 shows the planned sale of 20,739 shares from a restricted stock vest that occurred on 03/01/2025, to be executed via Merrill Lynch on 10/02/2025. This is a routine disclosure required when certain insiders or affiliates intend to sell shares after a vesting event.

The filing also documents prior insider sales totaling 45,937 shares for $812,132 in the past three months, indicating ongoing liquidity actions by the same filer. These are factual, disclosed transactions and do not, by themselves, indicate undisclosed company developments.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Arcutis (ARQT) disclose in this Form 144?

The filing reports a proposed sale of 20,739 common shares with an aggregate market value of $415,574, planned for 10/02/2025, acquired via restricted stock vesting on 03/01/2025.

Who is the seller named in the Form 144 for ARQT?

Past-sales records in the filing identify the seller as Todd Franklin Watanabe at the provided address.

How many ARQT shares were sold by the filer in the past three months?

The filer sold a total of 45,937 shares in the prior three months, generating gross proceeds of $812,132 across four transactions.

How were the shares being sold acquired?

The 20,739 shares planned for sale were acquired on 03/01/2025 through a restricted stock vest from Arcutis Biotherapeutics.

Which broker is handling the planned sale?

The filing lists Merrill Lynch, 8890 Lyra Drive, Columbus OH as the broker named for the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/02/2025 - 04:43 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801061
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics Inc.
SEC File Number	001-39186
Address of Issuer	3027 TOWNSGATE ROAD SUITE 300 WESTLAKE VILLAGE CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Todd Franklin Watanabe
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	20739	415574	119905078	10/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2025	Restricted Stock Vest	Arcutis Biotherapeutics			20739	03/01/2025	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Todd Franklin Watanabe 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	10/01/2025	24261	469074
Todd Franklin Watanabe 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	09/09/2025	504	8829
Todd Franklin Watanabe 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	09/08/2025	9625	168800
Todd Franklin Watanabe 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	08/04/2025	11547	165429

144: Remarks and Signature

Remarks
Date of Notice	10/02/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/03/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Todd Watanabe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)